Molecular mechanisms of HBV-associated hepatocarcinogenesis

Seminars in Liver Disease

Volumn 33, Issue 2, 2013, Pages 147-156

  Guerrieri, Francesca ^a   Belloni, Laura ^a,b   Pediconi, Natalia ^b,c   Levrero, Massimo ^a,b  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b ISTITUTO ITALIANO DI TECNOLOGIA   (Italy)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

epigenetics; HBx protein; hepatitis B virus (HBV); hepatocellular carcinoma (HCC); miRNAs

Indexed keywords

AFLATOXIN B1; ALPHA FETOPROTEIN; ANGIOPOIETIN 2; BETA CATENIN; COMPLEMENTARY DNA; CYCLIN 1; CYCLIN DEPENDENT KINASE; CYCLINE; DNA METHYLTRANSFERASE; EPITHELIAL CELL ADHESION MOLECULE; HEPATITIS B VIRUS X PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; MIXED LINEAGE LEUKEMIA PROTEIN; MIXED LINEAGE LEUKEMIA PROTEIN 4; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN P21; PROTEIN P53; REACTIVE OXYGEN METABOLITE; RHO KINASE; SENTRIN SPECIFIC PROTEASE 5; SMAD4 PROTEIN; SUMO 1 PROTEIN; TELOMERASE; TRANSCRIPTION FACTOR SNAIL; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; UNINDEXED DRUG; VIRUS DNA; WNT PROTEIN;

ANGIOGENESIS; APOPTOSIS; ARTICLE; CANCER RISK; CELL CYCLE ARREST; CELL PROLIFERATION; CHROMATIN; CHRONIC HEPATITIS; CHRONIC INFLAMMATION; DNA DAMAGE; DNA INTEGRATION; ENDOPLASMIC RETICULUM; EPIGENETICS; EPITHELIAL MESENCHYMAL TRANSITION; FIBROGENESIS; GENE EXPRESSION; GENE LOCUS; GENE MUTATION; HEPATITIS B VIRUS; HEPATITIS C; HUMAN; HYPOXIA; IMMUNE RESPONSE; LIVER CARCINOGENESIS; LIVER CELL; LIVER CELL CARCINOMA; LIVER FIBROSIS; MALIGNANT TRANSFORMATION; MOLECULAR MECHANICS; MUTAGENESIS; NONHUMAN; OPEN READING FRAME; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RISK FACTOR; SENESCENCE; STEM CELL; TELOMERE; TRANSCRIPTION REGULATION; TUMOR SUPPRESSOR GENE; VIRUS REPLICATION;

ANIMALS; CARCINOMA, HEPATOCELLULAR; CELL TRANSFORMATION, VIRAL; EPIGENESIS, GENETIC; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE EXPRESSION REGULATION, VIRAL; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HOST-PATHOGEN INTERACTIONS; HUMANS; LIVER NEOPLASMS; RISK FACTORS; SIGNAL TRANSDUCTION; TRANS-ACTIVATORS;

EID: 84878889935     PISSN: 02728087     EISSN: 10988971     Source Type: Journal    
DOI: 10.1055/s-0033-1345721     Document Type: Article

References (100)

1. Venook A. P., Papandreou C., Furuse J., de Guevara L. L. The incidence and epidemiology of hepatocellular carcinoma: a global and regional perspective. Oncologist: 2010; 15 04 5 13
2. El-Serag H. B., Rudolph K. L. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology: 2007; 132 7 2557 2576 (Pubitemid 46890874)
3. Fattovich G., Stroffolini T., Zagni I., Donato F. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology: 2004; 127 5 01 S35 S50 (Pubitemid 39423368)
4. Sherman M. Risk of hepatocellular carcinoma in hepatitis B and prevention through treatment. Cleve Clin J Med: 2009; 76 03 S6 S9
5. Raimondo G., Allain J. P., Brunetto M. R., et al. Statements from the Taormina expert meeting on occult hepatitis B virus infection. J Hepatol: 2008; 49 4 652 657
6. Ahn S. H., Park Y. N., Park J. Y., et al. Long-term clinical and histological outcomes in patients with spontaneous hepatitis B surface antigen seroclearance. J Hepatol: 2005; 42 2 188 194 (Pubitemid 40143464)
7. Pollicino T., Squadrito G., Cerenzia G., et al. Hepatitis B virus maintains its pro-oncogenic properties in the case of occult HBV infection. Gastroenterology: 2004; 126 1 102 110 (Pubitemid 38040728)
8. Pollicino T., Vegetti A., Saitta C., et al. Hepatitis B virus DNA integration in tumour tissue of a non-cirrhotic HFE-haemochromatosis patient with hepatocellular carcinoma. J Hepatol: 2013; 58 1 190 193
9. Chen C. J., Yang H. I., Su J., et al. REVEAL-HBV Study Group Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA: 2006; 295 1 65 73 (Pubitemid 43042691)
10. Levrero M., Pollicino T., Petersen J., Belloni L., Raimondo G., Dandri M. Control of cccDNA function in hepatitis B virus infection. J Hepatol: 2009; 51 3 581 592
11. Pollicino T., Belloni L., Raffa G., et al. Hepatitis B virus replication is regulated by the acetylation status of hepatitis B virus cccDNA-bound H3 and H4 histones. Gastroenterology: 2006; 130 3 823 837 (Pubitemid 43374531)
12. Bouchard M. J., Navas-Martin S. Hepatitis B and C virus hepatocarcinogenesis: lessons learned and future challenges. Cancer Lett: 2011; 305 2 123 143
13. European Association For The Study Of The Liver EASL Clinical Practice Guidelines: management of chronic hepatitis B. J Hepatol: 2009; 50 2 227 242
14. Papatheodoridis G. V., Lampertico P., Manolakopoulos S., Lok A. Incidence of hepatocellular carcinoma in chronic hepatitis B patients receiving nucleos(t)ide therapy: a systematic review. J Hepatol: 2010; 53 2 348 356
15. Hanahan D., Weinberg R. A. Hallmarks of cancer: the next generation. Cell: 2011; 144 5 646 674
16. Levrero M. Viral hepatitis and liver cancer: the case of hepatitis C. Oncogene: 2006; 25 27 3834 3847 (Pubitemid 43980479)
17. Wu J., Meng Z., Jiang M., et al. Hepatitis B virus suppresses toll-like receptor-mediated innate immune responses in murine parenchymal and nonparenchymal liver cells. Hepatology: 2009; 49 4 1132 1140
18. Aoki H., Kajino K., Arakawa Y., Hino O. Molecular cloning of a rat chromosome putative recombinogenic sequence homologous to the hepatitis B virus encapsidation signal. Proc Natl Acad Sci U S A: 1996; 93 14 7300 7304 (Pubitemid 26243544)
19. Gozuacik D., Murakami Y., Saigo K., et al. Identification of human cancer-related genes by naturally occurring hepatitis B virus DNA tagging. Oncogene: 2001; 20 43 6233 6240 (Pubitemid 32964436)
20. Murakami Y., Saigo K., Takashima H., et al. Large scaled analysis of hepatitis B virus (HBV) DNA integration in HBV related hepatocellular carcinomas. Gut: 2005; 54 8 1162 1168 (Pubitemid 41025914)
21. Ferber M. J., Montoya D. P., Yu C., et al. Integrations of the hepatitis B virus (HBV) and human papillomavirus (HPV) into the human telomerase reverse transcriptase (hTERT) gene in liver and cervical cancers. Oncogene: 2003; 22 24 3813 3820 (Pubitemid 36760744)
22. Paterlini-Bréchot P., Saigo K., Murakami Y., et al. Hepatitis B virus-related insertional mutagenesis occurs frequently in human liver cancers and recurrently targets human telomerase gene. Oncogene: 2003; 22 25 3911 3916 (Pubitemid 36819664)
23. Sung W. K., Zheng H., Li S., et al. Genome-wide survey of recurrent HBV integration in hepatocellular carcinoma. Nat Genet: 2012; 44 7 765 769
24. Fujimoto A., Totoki Y., Abe T., et al. Whole-genome sequencing of liver cancers identifies etiological influences on mutation patterns and recurrent mutations in chromatin regulators. Nat Genet: 2012; 44 7 760 764
25. Terradillos O., Billet O., Renard C. A., et al. The hepatitis B virus X gene potentiates c-myc-induced liver oncogenesis in transgenic mice. Oncogene: 1997; 14 4 395 404 (Pubitemid 27087102)
26. Chisari F. V., Klopchin K., Moriyama T., et al. Molecular pathogenesis of hepatocellular carcinoma in hepatitis B virus transgenic mice. Cell: 1989; 59 6 1145 1156 (Pubitemid 20024625)
27. Hsieh Y. H., Su I. J., Wang H. C., et al. Pre-S mutant surface antigens in chronic hepatitis B virus infection induce oxidative stress and DNA damage. Carcinogenesis: 2004; 25 10 2023 2032
28. Hildt E., Munz B., Saher G., Reifenberg K., Hofschneider P. H. The PreS2 activator MHBs(t) of hepatitis B virus activates c-raf-1/Erk2 signaling in transgenic mice. EMBO J: 2002; 21 4 525 535 (Pubitemid 34174034)
29. Levrero M., Belloni L. HBV Signaling. In: Clavien P. A., Dufour J. F., eds. Signaling Pathways in Liver Diseases. Berlin-Heidelberg Springer: 2010; 465 481
30. Belloni L., Pollicino T., De Nicola F., et al. Nuclear HBx binds the HBV minichromosome and modifies the epigenetic regulation of cccDNA function. Proc Natl Acad Sci U S A: 2009; 106 47 19975 19979
31. Lucifora J., Arzberger S., Durantel D., et al. Hepatitis B virus X protein is essential to initiate and maintain virus replication after infection. J Hepatol: 2011; 55 5 996 1003
32. Pang R., Lee T. K., Poon R. T., et al. Pin1 interacts with a specific serineproline motif of hepatitis B virus X-protein to enhance hepatocarcinogenesis. Gastroenterology: 2007; 132 3 1088 1103 (Pubitemid 46440863)
33. Wang W. H., Studach L. L., Andrisani O. M. Proteins ZNF198 and SUZ12 are down-regulated in hepatitis B virus (HBV) X protein-mediated hepatocyte transformation and in HBV replication. Hepatology: 2011; 53 4 1137 1147
34. Studach L. L., Menne S., Cairo S., et al. Subset of Suz12/PRC2 target genes is activated during hepatitis B virus replication and liver carcinogenesis associated with HBV X protein. Hepatology: 2012; 56 4 1240 1251
35. Park I. Y., Sohn B. H., Yu E., et al. Aberrant epigenetic modifications in hepatocarcinogenesis induced by hepatitis B virus X protein. Gastroenterology: 2007; 132 4 1476 1494 (Pubitemid 46627570)
36. Zheng D. L., Zhang L., Cheng N., et al. Epigenetic modification induced by hepatitis B virus X protein via interaction with de novo DNA methyltransferase DNMT3A. J Hepatol: 2009; 50 2 377 387
37. Cougot D., Wu Y., Cairo S., et al. The hepatitis B virus X protein functionally interacts with CREB-binding protein/p300 in the regulation of CREB-mediated transcription. J Biol Chem: 2007; 282 7 4277 4287 (Pubitemid 47100918)
38. Cougot D., Allemand E., Rivière L., et al. Inhibition of PP1 phosphatase activity by HBx: a mechanism for the activation of hepatitis B virus transcription. Sci Signal: 2012; 5 205 ra1
39. Guerrieri F., Scisciani C., Belloni L., et al. HBx-induced repression of mir224 expression relieves the direct inhibitory effects of mir224 on HBV pgRNA to potentiate hbv replication. 47th Annual Meeting of the European Association for the Study of the Liver (EASL) J Hepatol: 2012; 56 S2 S176
40. Guerrieri F., Belloni L., D'Andrea D., et al. A genome wide chromatin-immunoprecipitation (ChIPSeq) study identifies a broad repertoire of miRNAs as direct targets of HBx. 63rd Annual Meeting of the American- Association-for-the-Study-of-Liver-Diseases (AASLD). Hepatology: 2012; 56 S1 213A
41. Pan J., Lian Z., Wallett S., Feitelson M. A. The hepatitis B x antigen effector, URG7, blocks tumour necrosis factor α-mediated apoptosis by activation of phosphoinositol 3-kinase and β-catenin. J Gen Virol: 2007; 88 Pt 12 3275 3285 (Pubitemid 350201837)
42. Clippinger A. J., Bouchard M. J. Hepatitis B virus HBx protein localizes to mitochondria in primary rat hepatocytes and modulates mitochondrial membrane potential. J Virol: 2008; 82 14 6798 6811 (Pubitemid 351977701)
43. Cho H. K., Cheong K. J., Kim H. Y., Cheong J. Endoplasmic reticulum stress induced by hepatitis B virus X protein enhances cyclo-oxygenase 2 expression via activating transcription factor 4. Biochem J: 2011; 435 2 431 439
44. Yang B., Bouchard M. J. The hepatitis B virus X protein elevates cytosolic calcium signals by modulating mitochondrial calcium uptake. J Virol: 2012; 86 1 313 327
45. Li J., Liu Y., Wang Z., et al. Subversion of cellular autophagy machinery by hepatitis B virus for viral envelopment. J Virol: 2011; 85 13 6319 6333
46. Yoo Y. G., Oh S. H., Park E. S., et al. Hepatitis B virus X protein enhances transcriptional activity of hypoxia-inducible factor-1α through activation of mitogen-activated protein kinase pathway. J Biol Chem: 2003; 278 40 39076 39084 (Pubitemid 37221811)
47. Sanz-Cameno P., Martín-Vílchez S., Lara-Pezzi E., et al. Hepatitis B virus promotes angiopoietin-2 expression in liver tissue: role of HBV X protein. Am J Pathol: 2006; 169 4 1215 1222 (Pubitemid 351194358)
48. Arzumanyan A., Reis H. M., Feitelson M. A. Pathogenic mechanisms in HBV- and HCV-associated hepatocellular carcinoma. Nat Rev Cancer: 2013; 13 2 123 135
49. Kang T. W., Yevsa T., Woller N., et al. Senescence surveillance of pre-malignant hepatocytes limits liver cancer development. Nature: 2011; 479 7374 547 551
50. Wiemann S. U., Satyanarayana A., Tsahuridu M., et al. Hepatocyte telomere shortening and senescence are general markers of human liver cirrhosis. FASEB J: 2002; 16 9 935 942 (Pubitemid 34753499)
51. Plentz R. R., Park Y. N., Lechel A., et al. Telomere shortening and inactivation of cell cycle checkpoints characterize human hepatocarcinogenesis. Hepatology: 2007; 45 4 968 976 (Pubitemid 46631565)
52. Kojima H., Yokosuka O., Imazeki F., Saisho H., Omata M. Telomerase activity and telomere length in hepatocellular carcinoma and chronic liver disease. Gastroenterology: 1997; 112 2 493 500 (Pubitemid 27078836)
53. Ozturk M., Arslan-Ergul A., Bagislar S., Senturk S., Yuzugullu H. Senescence and immortality in hepatocellular carcinoma. Cancer Lett: 2009; 286 1 103 113
54. Kawai H., Suda T., Aoyagi Y., et al. Quantitative evaluation of genomic instability as a possible predictor for development of hepatocellular carcinoma: comparison of loss of heterozygosity and replication error. Hepatology: 2000; 31 6 1246 1250 (Pubitemid 30351285)
55. Forgues M., Difilippantonio M. J., Linke S. P., et al. Involvement of Crm1 in hepatitis B virus X protein-induced aberrant centriole replication and abnormal mitotic spindles. Mol Cell Biol: 2003; 23 15 5282 5292 (Pubitemid 36950883)
56. Collado M., Gil J., Efeyan A., et al. Tumour biology: senescence in premalignant tumours. Nature: 2005; 436 7051 642 (Pubitemid 41117258)
57. Benn J., Schneider R. J. Hepatitis B virus HBx protein activates Ras-GTP complex formation and establishes a Ras, Raf, MAP kinase signaling cascade. Proc Natl Acad Sci U S A: 1994; 91 22 10350 10354 (Pubitemid 24328994)
58. Chung T. W., Lee Y. C., Kim C. H. Hepatitis B viral HBx induces MMP-9 gene expression through activation of ERK and PI-3K/AKT pathways: involvement of invasive potential. FASEB J: 2004; 18 10 1123 1125
59. Tarn C., Lee S., Hu Y., Ashendel C., Andrisani O. M. Hepatitis B virus X protein differentially activates RAS-RAF-MAPK and JNK pathways in X-transforming versus non-transforming AML12 hepatocytes. J Biol Chem: 2001; 276 37 34671 34680
60. Huang J., Wang Y., Guo Y., Sun S. Down-regulated microRNA-152 induces aberrant DNA methylation in hepatitis B virus-related hepatocellular carcinoma by targeting DNA methyltransferase 1. Hepatology: 2010; 52 1 60 70
61. Wang X. W., Forrester K., Yeh H., Feitelson M. A., Gu J. R., Harris C. C. Hepatitis B virus X protein inhibits p53 sequence-specific DNA binding, transcriptional activity, and association with transcription factor ERCC3. Proc Natl Acad Sci U S A: 1994; 91 6 2230 2234 (Pubitemid 24092077)
62. Zhao J., Wu G., Bu F., et al. Epigenetic silence of ankyrin-repeat- containing, SH3-domain-containing, and proline-rich-region- containing protein 1 (ASPP1) and ASPP2 genes promotes tumor growth in hepatitis B virus-positive hepatocellular carcinoma. Hepatology: 2010; 51 1 142 153
63. Park S. H., Jung J. K., Lim J. S., Tiwari I., Jang K. L. Hepatitis B virus X protein overcomes all-trans retinoic acid-induced cellular senescence by downregulating levels of p16 and p21 via DNA methylation. J Gen Virol: 2011; 92 Pt 6 1309 1317
64. Zender L., Xue W., Zuber J., et al. An oncogenomics-based in vivo RNAi screen identifies tumor suppressors in liver cancer. Cell: 2008; 135 5 852 864
65. Castilla A., Prieto J., Fausto N. Transforming growth factors β 1 and α in chronic liver disease. Effects of interferon alfa therapy. N Engl J Med: 1991; 324 14 933 940
66. Barrallo-Gimeno A., Nieto M. A. The Snail genes as inducers of cell movement and survival: implications in development and cancer. Development: 2005; 132 14 3151 3161 (Pubitemid 41167144)
67. van Zijl F., Zulehner G., Petz M., et al. Epithelial-mesenchymal transition in hepatocellular carcinoma. Future Oncol: 2009; 5 8 1169 1179
68. Yoo Y. D., Ueda H., Park K., et al. Regulation of transforming growth factor-β 1 expression by the hepatitis B virus (HBV) X transactivator. Role in HBV pathogenesis. J Clin Invest: 1996; 97 2 388 395
69. Lee D. K., Park S. H., Yi Y., et al. The hepatitis B virus encoded oncoprotein pX amplifies TGF-β family signaling through direct interaction with Smad4: potential mechanism of hepatitis B virus-induced liver fibrosis. Genes Dev: 2001; 15 4 455 466 (Pubitemid 32187006)
70. Xu J., Lamouille S., Derynck R. TGF-β-induced epithelial to mesenchymal transition. Cell Res: 2009; 19 2 156 172
71. Battaglia S., Benzoubir N., Nobilet S., et al. Liver cancer-derived hepatitis C virus core proteins shift TGF-β responses from tumor suppression to epithelial-mesenchymal transition. PLoS ONE: 2009; 4 2 e4355
72. Zhu Q., Wang Z., Hu Y., et al. miR-21 promotes migration and invasion by the miR-21-PDCD4-AP-1 feedback loop in human hepatocellular carcinoma. Oncol Rep: 2012; 27 5 1660 1668
73. Yang S. Z., Zhang L. D., Zhang Y., et al. HBx protein induces EMT through c-Src activation in SMMC-7721 hepatoma cell line. Biochem Biophys Res Commun: 2009; 382 3 555 560
74. Lara-Pezzi E., Roche S., Andrisani O. M., Sánchez-Madrid F., López-Cabrera M. The hepatitis B virus HBx protein induces adherens junction disruption in a src-dependent manner. Oncogene: 2001; 20 26 3323 3331 (Pubitemid 32588980)
75. Arzumanyan A., Friedman T., Kotei E., Ng I. O., Lian Z., Feitelson M. A. Epigenetic repression of E-cadherin expression by hepatitis B virus X antigen in liver cancer. Oncogene: 2012; 31 5 563 572
76. Sell S., Leffert H. L. Liver cancer stem cells. J Clin Oncol: 2008; 26 17 2800 2805
77. Yamashita T., Budhu A., Forgues M., Wang X. W. Activation of hepatic stem cell marker EpCAM by Wnt-β-catenin signaling in hepatocellular carcinoma. Cancer Res: 2007; 67 22 10831 10839 (Pubitemid 350145912)
78. Roskams T. Liver stem cells and their implication in hepatocellular and cholangiocarcinoma. Oncogene: 2006; 25 27 3818 3822 (Pubitemid 43980477)
79. Lee J. S., Heo J., Libbrecht L., et al. A novel prognostic subtype of human hepatocellular carcinoma derived from hepatic progenitor cells. Nat Med: 2006; 12 4 410 416
80. Yamashita T., Ji J., Budhu A., et al. EpCAM-positive hepatocellular carcinoma cells are tumor-initiating cells with stem/progenitor cell features. Gastroenterology: 2009; 136 3 1012 1024
81. Ji J., Yamashita T., Budhu A., et al. Identification of microRNA-181 by genome-wide screening as a critical player in EpCAM-positive hepatic cancer stem cells. Hepatology: 2009; 50 2 472 480
82. Chan H. L., Hui A. Y., Wong M. L., et al. Genotype C hepatitis B virus infection is associated with an increased risk of hepatocellular carcinoma. Gut: 2004; 53 10 1494 1498 (Pubitemid 39265273)
83. Kao J. H., Chen P. J., Lai M. Y., Chen D. S. Basal core promoter mutations of hepatitis B virus increase the risk of hepatocellular carcinoma in hepatitis B carriers. Gastroenterology: 2003; 124 2 327 334
84. Kuang S. Y., Jackson P. E., Wang J. B., et al. Specific mutations of hepatitis B virus in plasma predict liver cancer development. Proc Natl Acad Sci U S A: 2004; 101 10 3575 3580 (Pubitemid 38338237)
85. Zoulim F., Locarnini S. Hepatitis B virus resistance to nucleos(t)ide analogues. Gastroenterology: 2009; 137 5 1593 1608, e1-e2
86. Warner N., Locarnini S. The antiviral drug selected hepatitis B virus rtA181T/sW172* mutant has a dominant negative secretion defect and alters the typical profile of viral rebound. Hepatology: 2008; 48 1 88 98 (Pubitemid 351975534)
87. Yeh C. T., Chen T., Hsu C. W., et al. Emergence of the rtA181T/sW172* mutant increased the risk of hepatoma occurrence in patients with lamivudine-resistant chronic hepatitis B. BMC Cancer: 2011; 11 398
88. Nault J. C., Zucman-Rossi J. Genetics of hepatobiliary carcinogenesis. Semin Liver Dis: 2011; 31 2 173 187
89. Sia D., Villanueva A. Signaling pathways in hepatocellular carcinoma. Oncology: 2011; 81 01 18 23
90. Laurent-Puig P., Legoix P., Bluteau O., et al. Genetic alterations associated with hepatocellular carcinomas define distinct pathways of hepatocarcinogenesis. Gastroenterology: 2001; 120 7 1763 1773 (Pubitemid 32523494)
91. Guichard C., Amaddeo G., Imbeaud S., et al. Integrated analysis of somatic mutations and focal copy-number changes identifies key genes and pathways in hepatocellular carcinoma. Nat Genet: 2012; 44 6 694 698
92. Boyault S., Rickman D. S., de Reyniès A., et al. Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets. Hepatology: 2007; 45 1 42 52 (Pubitemid 46144363)
93. Hoshida Y., Moeini A., Alsinet C., Kojima K., Villanueva A. Gene signatures in the management of hepatocellular carcinoma. Semin Oncol: 2012; 39 4 473 485
94. Imbeaud S., Ladeiro Y., Zucman-Rossi J. Identification of novel oncogenes and tumor suppressors in hepatocellular carcinoma. Semin Liver Dis: 2010; 30 1 75 86
95. Zhang X., Liu S., Hu T., Liu S., He Y., Sun S. Up-regulated microRNA-143 transcribed by nuclear factor kappa B enhances hepatocarcinoma metastasis by repressing fibronectin expression. Hepatology: 2009; 50 2 490 499
96. Ura S., Honda M., Yamashita T., et al. Differential microRNA expression between hepatitis B and hepatitis C leading disease progression to hepatocellular carcinoma. Hepatology: 2009; 49 4 1098 1112
97. Wang Y., Lu Y., Toh S. T., et al. Lethal-7 is down-regulated by the hepatitis B virus X protein and targets signal transducer and activator of transcription 3. J Hepatol: 2010; 53 1 57 66
98. Ji J., Shi J., Budhu A., et al. MicroRNA expression, survival, and response to interferon in liver cancer. N Engl J Med: 2009; 361 15 1437 1447
99. Calvisi D. F., Ladu S., Gorden A., et al. Mechanistic and prognostic significance of aberrant methylation in the molecular pathogenesis of human hepatocellular carcinoma. J Clin Invest: 2007; 117 9 2713 2722 (Pubitemid 47494371)
100. Zhao J., Wu G., Bu F., et al. Epigenetic silence of ankyrin-repeat- containing, SH3-domain-containing, and proline-rich-region- containing protein 1 (ASPP1) and ASPP2 genes promotes tumor growth in hepatitis B virus-positive hepatocellular carcinoma. Hepatology: 2010; 51 1 142 153